The FDA has approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) from AbbVie, an all-oral, interferon-free...
In consultation with the FDA, the US prescribing information for Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and...
AbbVie’s New Drug Application (NDA) has been accepted by the FDA for a once-daily, fixed-dose formulation of the components of...
The FDA has approved a supplemental New Drug Application (sNDA) for the use of Viekira Pak (ombitasvir, paritaprevir, and ritonavir...
AbbVie has announced new data from its ongoing Phase IIIb TOPAZ-II study evaluating Viekira Pak (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir...
The FDA has approved Quillivant XR (methylphenidate hydrochloride) from Next Wave Pharma for extended-release oral suspension for treatment of Attention...
The Federal Patent Court in Germany has found the formulation patent protecting Seroquel XR (quetiapine fumarate) prolonged-release tablets � marketed...
The FDA has informed Veloxis of the tentative approval of Envarsus XR (tacrolimus extended relief) for Transplant Rejection. The FDA...
Pfizer has announced that the FDA has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment...